As much as it pains me, I have to side with Bert.
When being detailed, I realize the data is presented in such a way as to make the particular medication, seem like the next best thing made since apple pie. But it is data that needs to be analyzed in the context of other data, and like David utilize up to date, epocrates, and medscape on a daily level.
But ultimately it is up to the individual practitioner to decide what to prescribe after having a rational discussion with his patient.
However, with that being said, I would be willing to go hungry for lunch, if the pharmaceutical companies would do away with their gimmick % off the cost of med cards (that aren't even available for the medicare patient who needs the help the most), equalize the cost of med across borders (as there is no reason why my patients should get the same branded med in Mexico or Canada for a fraction of the cost) in order to reduce the cost of branded drugs.
I do buy pens now, except the free one I received from the government for filling out their EHR user survey--
